<DOC>
	<DOCNO>NCT01451333</DOCNO>
	<brief_summary>Persistent HIV infection central nervous system ( CNS ) compartment may put subject risk develop HIV-related brain disease . Important factor associate development HIV-related brain disease include therapeutic concentration antiretroviral drug CNS . Conflicting evidence regard CNS exposure antiretroviral drug use encore1 study , efavirenz ( EFV ) describe related study . There recent study two small series assessment EFV exposure cerebral spinal fluid ( CSF ) ; one group report small detectable EFV concentration , another observe undetectable EFV exposure CSF . Also , large report series comprise 80 subject EFV-containing antiretroviral therapy , CSF plasma concentration suggest limited movement EFV CSF . In HIV-1 infected subject steady state , EFV plasma level parameter dose proportional follow 200mg , 400mg , 600mg daily dos . The CNS exposure EFV different daily dose describe .</brief_summary>
	<brief_title>The Efavirenz ( EFV ) Central Nervous System Exposure Sub-study Encore1</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>All subject enter main study protocol participate centre eligible enter substudy . Existing neurological disease opinion investigator would contraindication lumbar puncture examination CNS opportunistic infection past 12 week randomisation Bacterial viral meningitis past 12 week randomisation Head injury require medical assessment past 12 week randomisation</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Central Nervous System ( CNS )</keyword>
	<keyword>Lumbar puncture</keyword>
	<keyword>Dose reduction</keyword>
</DOC>